WELCOME TO HDL THERAPEUTICS, INC.

We have developed the first therapy of its kind to rapidly reverse coronary atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH).

Our innovative acute care therapeutic device called PDS-2™ System transforms a patient’s own plasma into an atherosclerostic reversal agent using our patented technology to allow for rapid regression of plaque in coronary arteries of patients with HoFH.

We have a novel SAR-CoV-2 Viral Delipidation Therapy that is expected to create an enhanced immune response with a faster and more cost-effective method of development.